Anixa Biosciences INC Form 4 insider transactions

Anixa Biosciences CEO Amit Kumar purchased 43,000 shares of the company's common stock at $2.23 per share on January 15, 2025.

Michael Catelani, President, COO, & CFO of Anixa Biosciences, reports a transaction involving the company's common stock on January 15, 2025.

Lewis H. Titterton Jr., a director of Anixa Biosciences, Inc., was granted employee stock options for 25,000 shares on January 2, 2025.

Emily Gottschalk, a director of Anixa Biosciences, acquired 25,000 employee stock options on January 2, 2025, according to a Form 4 filing with the SEC.

Anixa Biosciences CEO Amit Kumar was granted 700,000 employee stock options on January 2, 2025, according to a Form 4 filing.

Director Arnold M. Baskies acquired 25,000 employee stock options in Anixa Biosciences Inc. on January 2, 2025, according to a Form 4 filing.

Michael Catelani, President, COO & CFO of Anixa Biosciences, Inc., reports the acquisition of 350,000 employee stock options.

Lewis H. Titterton Jr., a director of Anixa Biosciences, exercised stock options to acquire 16,000 shares of common stock at $2.575 per share on October 22, 2024.

Director Lewis H. Titterton Jr. reports purchasing additional shares of Anixa Biosciences, Inc. on July 30 and 31, 2024.

Director Lewis H. Titterton Jr. has increased his holdings in Anixa Biosciences through recent stock purchases.

Anixa Biosciences Director Arnold M. Baskies reports purchasing 5,000 shares of common stock at $3.09 per share on July 26, 2024, increasing his total holdings to 115,000 shares.

Lewis H. Titterton Jr., a director at Anixa Biosciences, recently purchased 4,000 shares of common stock, increasing his total holdings to 860,612 shares.

Director Lewis H. Titterton Jr. of Anixa Biosciences Inc. [ANIX] purchased 405 shares of common stock on June 13, 2024, at a price of $2.7 per share.

Director Lewis H. Titterton Jr. reports purchasing additional shares of Anixa Biosciences, Inc. common stock.

Director Lewis H. Titterton Jr. of Anixa Biosciences Inc. purchased 10,738 shares of common stock at $2.52 per share on June 7, 2024.

Michael Catelani, President, COO, & CFO of Anixa Biosciences, Inc., reports purchasing 6,250 shares of common stock at $2.40 per share on June 7, 2024.

Anixa Biosciences CEO Amit Kumar purchased 25,000 shares of common stock at $2.41 per share on June 7, 2024.

Anixa Biosciences' President, COO, & CFO, Michael Catelani, reports acquiring shares through the Employee Stock Purchase Plan and disposing of shares.

Anixa Biosciences Director Lewis H. Titterton Jr. purchased 15,009 shares of common stock at a price of $3.28 per share on April 9, 2024.

Anixa Biosciences Director Arnold M. Baskies purchased 10,000 shares of common stock at $3.63 per share on March 15, 2024.

Anixa Biosciences CEO Amit Kumar reports purchasing 30,000 shares of the company's common stock at $3.22 per share on March 15, 2024.